8-K: Artivion Delivers Strong 2025 Growth, Positive Clinical Data

Artivion, Inc. announced robust financial results for Q4 and full year 2025, driven by double-digit revenue and EBITDA growth, alongside positive clinical trial data and regulatory progress.

Summary

• GAAP revenue for the fourth quarter of 2025 was $116.0 million, an increase from $97.3 million in the fourth quarter of 2024.
• For the full year 2025, GAAP revenue reached $441.3 million, up from $388.5 million in 2024.
• GAAP net income for Q4 2025 was $2.4 million, or $0.05 per fully diluted share, a significant improvement from a net loss of $(16.5) million, or $(0.39) per fully diluted share, in Q4 2024.
• Full year 2025 GAAP net income was $9.8 million, reversing a net loss of $(13.4) million for the full year 2024.
• Adjusted revenue for Q4 2025 increased 18% on an adjusted constant currency basis to $118.3 million.
• Full year 2025 adjusted revenue grew 13% on an adjusted constant currency basis to $443.6 million.
• Adjusted EBITDA increased 29% to $22.7 million in Q4 2025 and 26% to $89.6 million for the full year 2025.
• The company filed the fourth and final module of its pre-market approval application (PMA) to the FDA for the AMDS Hybrid Prothesis.
• Positive new clinical data from Endospan's NEXUS TRIOMPHE IDE trial demonstrated 94% patient survival from lesion-related death and 91% of patients remaining free from disabling stroke at 1-year post-treatment.
• Positive 2-year data from the AMDS PERSEVERE IDE trial further demonstrated persistent clinical benefits of the AMDS technology.
• A $2.3 million reserve was recorded as a reduction to revenue for estimated payback to the Italian government for fiscal years 2019 through 2025 due to new legislation.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, reflecting strong financial performance, significant progress in clinical trials and regulatory approvals, and an optimistic outlook for sustained growth in a specialized medical device market.

Positives

• Significant improvement in GAAP net income, moving from a loss of $(16.5) million in Q4 2024 to a profit of $2.4 million in Q4 2025, and from a loss of $(13.4) million in full year 2024 to a profit of $9.8 million in full year 2025.
• Strong adjusted constant currency revenue growth of 18% in Q4 2025 and 13% for the full year 2025.
• Robust adjusted EBITDA growth of 29% to $22.7 million in Q4 2025 and 26% to $89.6 million for the full year 2025.
• Double-digit growth across key product categories in Q4 2025 on an adjusted constant currency basis: stent grafts (36%), On-X (24%), and preservation services (6%).
• Successful filing of the fourth and final module of the PMA to the FDA for the AMDS Hybrid Prothesis, indicating significant progress towards market approval.
• Positive clinical data from Endospan's NEXUS TRIOMPHE IDE trial, demonstrating high patient survival (94%) and low morbidity (91% free from disabling stroke at 1-year) in a high-risk patient group.
• Positive 2-year data from the AMDS PERSEVERE IDE trial, reinforcing the persistent clinical benefits of AMDS technology.
• Strong 2026 financial outlook with expected revenue growth of 10% to 14% and adjusted EBITDA growth of 18% to 22%.

Negatives

• A $2.3 million reserve was recorded as a reduction to revenue for estimated payback to the Italian government for fiscal years 2019 through 2025 as a result of new legislation.

Risks

• The unpredictability of the timing and outcome of regulatory decisions and other regulatory developments.
• Risks relating to international operations.
• Anticipated benefits from the 2024 credit facility and 2025 amendments, the Ascyrus Medical LLC transaction, Endospan agreements, and operational improvements in the tissue and stent graft business may not be achieved at all or at the levels anticipated.
• Anticipated benefits from clinical trials and regulatory approvals may not be achieved or achieved on anticipated timelines.
• Anticipated benefits from expansion into APAC and LATAM regions may not be achieved or achieved on anticipated timelines.
• Future financial performance could differ significantly from management expectations and from results expressed or implied in the press release due to various risks and uncertainties.

Future Outlook

Artivion anticipates full year 2026 revenues to be between $486 million and $504 million, representing 10% to 14% growth on an adjusted constant currency basis. Adjusted EBITDA is projected to grow 18% to 22%, reaching an expected range of $105 million to $110 million for 2026. The company aims for sustained double-digit constant currency revenue growth and adjusted EBITDA growth at twice the pace of constant currency revenue growth over the long-term.

Management Comments

• "We are very pleased with our strong performance for the full year 2025 as we drove 13% adjusted constant currency revenue growth and 26% adjusted EBITDA growth, while making substantial progress in advancing our Aortic focused product development pipeline."
• "Our success continued through the fourth quarter, during which revenue growth was driven by year-over-year growth in stent grafts of 44%, On-X of 25%, and preservation services of 6%, all compared to the fourth quarter of 2024."
• "We were also pleased to see Endospan present positive new clinical data for its NEXUS TRIOMPHE IDE trial at the Society of Thoracic Surgery Annual Meeting. These results highlighted 94% patient survival from lesion-related death with 91% of patients remaining free from disabling stroke at 1-year post treatment in this high-risk patient group."
• "Entering 2026, we expect to build on our strong financial performance and continued clinical and operational achievements, reinforcing our confidence in our ability to deliver sustained double-digit constant currency revenue growth and adjusted EBITDA growth at twice the pace of constant currency revenue growth over the long-term."

Industry Context

StockSavvy.ai notes that Artivion's focus on aortic disease positions it within a specialized and growing segment of the medical device industry. The strong performance in stent grafts and On-X mechanical heart valves suggests effective market penetration and product demand, aligning with broader trends of innovation in cardiovascular care. The positive clinical trial data for NEXUS TRIOMPHE and AMDS PERSEVERE further strengthens its competitive standing in advanced aortic repair solutions.

Comparison to Industry Standards

• The filing does not contain specific comparisons to industry-standard companies, projects, or results.
• However, the reported 13% adjusted constant currency revenue growth and 26% adjusted EBITDA growth for the full year 2025 are robust, potentially outperforming many general medical device companies.
• The clinical outcomes of 94% patient survival and 91% freedom from disabling stroke at 1-year for high-risk patients in the NEXUS TRIOMPHE trial represent strong results for complex aortic interventions, which are generally associated with higher risks.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, return to profitability, robust growth in key metrics (revenue, EBITDA), positive clinical trial results, and optimistic future outlook, potentially leading to increased share value.
• Customers (Surgeons/Hospitals): Positive impact from new and improved medical devices (AMDS Hybrid Prothesis, Endospan NEXUS TRIOMPHE) offering better patient outcomes and expanded treatment options for aortic diseases.
• Employees: Positive impact from a growing and profitable company, potentially leading to job security, growth opportunities, and improved morale.
• Regulatory Authorities (FDA): Continued engagement through the PMA process for AMDS Hybrid Prothesis, demonstrating compliance and commitment to bringing innovative solutions to market.

Next Steps

• Building on strong financial performance and continued clinical and operational achievements in 2026.
• Delivering sustained double-digit constant currency revenue growth over the long-term.
• Delivering adjusted EBITDA growth at twice the pace of constant currency revenue growth over the long-term.
• Continuing to advance the Aortic focused product development pipeline.
• Potentially receiving FDA approval for the AMDS Hybrid Prothesis following the PMA filing.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance for both Q4 and the full year 2025, marked by a significant turnaround from net losses to profitability and robust double-digit growth in adjusted revenue and EBITDA. The positive clinical trial data for key products like Endospan's NEXUS TRIOMPHE and AMDS PERSEVERE, coupled with the completion of the PMA filing for the AMDS Hybrid Prothesis, indicate a strong product pipeline and significant future market opportunities. The optimistic 2026 guidance, projecting continued strong growth, further reinforces a positive investment thesis. Despite the Italian payback reserve, the overall trajectory and operational execution suggest a compelling 'strong buy' for long-term investors.

Keywords

Artivion, AORT, financial results, Q4 2025, full year 2025, aortic disease, stent grafts, On-X heart valves, surgical sealants, EBITDA, revenue growth, clinical trials, FDA PMA, medical devices, cardiac surgery, vascular surgery, Endospan, AMDS Hybrid Prothesis, NEXUS TRIOMPHE, PERSEVERE IDE